EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

1997-03-01

European Journal of Cancer , Volume 33 - Issue 3 p. 493- 495

Additional Metadata
Keywords	immunotherapy, linomide, renal cell carcinoma
Persistent URL	doi.org/10.1016/S0959-8049(97)89027-2, hdl.handle.net/1765/67178
Journal	European Journal of Cancer
Rights	no subscription
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Wit, R., Pawinsky, A., Stoter, G., van Oosterom, A., Fossa, S., Paridaens, R., … de Mulder, P. (1997). EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. European Journal of Cancer, 33(3), 493–495. doi:10.1016/S0959-8049(97)89027-2

Publication